Merus N.V. announced on May 15, 2025, the publication of petosemtamab's mechanism of action in the scientific journal 'Cancers'. The publication outlines the scientific rationale for this bispecific antibody, which targets Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5).
Petosemtamab employs three distinct mechanisms: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system through ADCP and ADCC. This multi-pronged approach is designed to address cancer growth, treatment resistance, and recurrence.
This scientific validation underpins the strong interim Phase 2 clinical data previously reported for petosemtamab in both 1L PD-L1+ r/m HNSCC in combination with pembrolizumab and as a single-agent in 2L+ r/m HNSCC. It reinforces the biological basis for its observed clinical activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.